APA (7th ed.) Citation

Yang, L., Cao, X., Li, N., Zheng, B., Liu, M., & Cai, H. (2022, August). Cost-effectiveness analysis of nivolumab plus ipilimumab chemotherapy as the first-line treatment for unresectable malignant pleural mesothelioma. Therapeutic Advances in Medical Oncology.

Chicago Style (17th ed.) Citation

Yang, Liu, Xueqiong Cao, Na Li, Bin Zheng, Maobai Liu, and Hongfu Cai. "Cost-effectiveness Analysis of Nivolumab Plus Ipilimumab Chemotherapy as the First-line Treatment for Unresectable Malignant Pleural Mesothelioma." Therapeutic Advances in Medical Oncology Aug. 2022.

MLA (9th ed.) Citation

Yang, Liu, et al. "Cost-effectiveness Analysis of Nivolumab Plus Ipilimumab Chemotherapy as the First-line Treatment for Unresectable Malignant Pleural Mesothelioma." Therapeutic Advances in Medical Oncology, Aug. 2022.